Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Thu, 01st Apr 2021 12:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based live biotherapeutic products developer - Posts pretax loss of GBP30.3 million in 2020, widening from GBP29.0 million a year prior. Revenue more-than-doubles to GBP534,000 from GBP211,000. Administrative expenses double to GBP9.1 million from GBP4.4 million. "4D has made significant progress leading the field in the development of live biotherapeutics, and made great strides from a corporate perspective. In addition to the data we have generated in the field of oncology, we completed our merger with Longevity and obtained a NASDAQ listing which, together with a concurrent fundraise, provides 4D with approximately USD40 million of additional capital and a solid financial footing moving forward. This puts 4D pharma in a strong position to capitalise on multiple data readouts from our ongoing trials in asthma and oncology as well as facilitating the move into the clinic with our Parkinson's disease programme," says 4D Pharma.

----------

Sportech PLC - Edinburgh-based gambling technology firm - Posts pretax loss from continuing operations for 2020 of GBP10.6 million, widening 9.3% from GBP9.7 million a year prior. Revenue sinks to GBP20.0 million from GBP33.6 million. "Providing a long-term projection with any degree of certainty in this environment is challenging and unrealistic, however having negotiated several corporate transactions during the last 12 months, when completed, the group will have reduced investors' risk and simplified the structure and the opportunities ahead," says Sportech.

----------

BSF Enterprise PLC - UK-based company formed to undertake an acquisition - Posts pretax loss of GBP93,845 in the year ended September 30, 2020, narrowed from GBP94,398 a year prior. "In the context of this challenging capital raising environment during this Covid-19 pandemic, I believe that BSF represents an extremely attractive proposition to prospective acquisition counterparties considering listing on the London Stock Exchange and I remain confident that we will be able to execute an acquisition that creates value for our shareholders," says BSF.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Posts net asset value per share at December 30 of 113.58 pence, in its annual report for the period from incorporation on October 22, 2019 to December 30, 2020. NAV per share increases 14% since IPO. Declares inaugural dividend of 0.85p per share. Says it will not target a dividend for future years but will substantially pay out distributable income for any particular period by way of dividend.

----------

Syncona Ltd - investor in life science companies - Notes results of portfolio company and biotechnology firm Freeline Therapeutics Holdings PLC. Freeline posts pretax loss for 2020 of USD96.2 million, widening from USD53.8 million a year prior. Research & development costs increase to USD76.1 million from USD47.0 million. "We are pleased with our current progress and aim to have three Freeline programs in the clinic by the end of 2021," said Theresa Heggie, Chief Executive Officer of Freeline.

----------

Horizonte Minerals PLC - nickel company focused on Brazil - Posts pretax loss of GBP2.6 million in 2020, widening 13% from GBP2.3 million a year prior. Administrative expenses increase to GBP2.9 million from GBP2.6 million. Says assets are not generating revenues. Does not declare any dividend in 2020, unchanged from a year prior. "The Covid-19 pandemic was unfortunately not an isolated event in 2020, it has continued in to 2021 and we will continue to feel its effects well into the medium term. However, with the accelerating rollout of a number of vaccines we are hopeful for a more certain, less interrupted year in 2021," says Horizonte.

----------

Proteome Sciences PLC - drug development services provider - Posts pretax profit of GBP245,000 in 2020, swinging from a loss of GBP36,000 a year before. Revenue increases to GBP4.8 million from GBP4.7 million. Administrative expenses fall 25% to GBP2.0 million from GBP2.7 million. "We have started an internal analysis on growing our business further in addition to our current activities. We believe that with our specialist expertise the market for our niche services has the potential to grow substantially as proteomics plays an increasingly vital role in drug discovery, development and in the response to current and future medical challenges," says Proteome.

----------

Arbuthnot Banking Group PLC - London-based private and commercial banking - Says subsidiary Arbuthnot Latham completes acquisition of provider of vehicle finance Asset Alliance Group Holdings Ltd. Says the consideration is now anticipated to be approximately GBP10.1 million.

----------

Stanley Gibbons Group PLC - London-based collectible postage stamp retailer - Says it has seen increased levels of digital activity and remote selling of albums and accessories contrasting with lower levels of high ticket sales and in person activities as a result of the third lockdown throughout the year to March 31. Says second half trading was better than the first. "We are hopeful that a vaccine led relaxing of restrictions is not only permanent but encourages activity levels to return at pace, however, this is hard to predict and we have plans in place if this is not how things develop," says Stanley Gibbons.

----------

Great Western Mining Corp PLC - mineral exploration and development company with gold, silver and copper assets in the US - Says drilling has start in Nevada to test a prospective copper target and is likely to be followed by a second hole on the same prospect. "This is an exciting moment for the company, being the first time in its history that it has launched a major drilling campaign for precious metals, while a recent fund-raising will enable us to expand the programme where appropriate," says Chair Brian Hall.

----------

Macfarlane Group PLC - Glasgow-based packaging firm - Announces acquisition of Carters Packaging Ltd in Cornwall. Carters is a distributor of protective packaging in the south-west of England. The acquisition will go for a maximum cash consideration of GBP4.5 million.

----------

1Spatial PLC - Cambridge-based location data software provider - Announces a multiyear contract with Defra to provide a managed service for Rural Payments Agency's Customer Portal and Land Management System. The total potential contract value over five years for 1Spatial is in excess of GBP900,000. The first three years will net the company GBP600,000, or GBP200,000 a year, while Defra has an option to extend for a further two years for GBP300,000.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 May 2018 16:11

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific

Read more
8 May 2018 10:02

4D Pharma Sets Up Phase Two Study For Bowel Syndrome Treatment Blautix

LONDON (Alliance News) - Biotherapeutics developer 4D Pharma PLC said on Tuesday that the US Food & Drug Administration has cleared the Investigational New Drug Application for irritable bowel

Read more
23 Apr 2018 09:47

4D Pharma Loss In 2017 Widens On Higher Research And Development Costs

LONDON (Alliance News) - Drug development firm 4D Pharma PLC said Monday its loss widened in 2017 on higher research and development costs as it continued to progress its pipeline and clinical in

Read more
21 Mar 2018 09:12

4D Pharma To Shortly Begin Clinical Studies On MRx0518 Treatment

LONDON (Alliance News) - 4D Pharma PLC on Wednesday said it is close to starting clinical studies on its potential MRx0518 cancer treatment.MRx0518 is a single strain a

Read more
13 Dec 2016 07:54

4D Pharma Reports Encouraging Results From Blautix Phase 1 Trial

Read more
30 Sep 2016 06:51

4D Pharma Loss Narrows As Operating And Research Costs Fall

Read more
22 Aug 2016 11:57

4D Pharma begins Thetanix phase 1 clinical trial

(ShareCast News) - Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or sw

Read more
19 Jul 2016 10:00

4D Pharma announces encouraging first clinical trial of Blautix

(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p

Read more
19 Jul 2016 07:49

4D Pharma Says Positive First Trial Of Product Blautix "Encouraging"

Read more
10 Jun 2016 07:30

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

Read more
23 May 2016 12:49

4D Pharma irritable bowel treatment proves safe in clinical trial

(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro

Read more
23 May 2016 06:58

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

Read more
17 May 2016 15:11

AGM, EGM Calendar - Week Ahead

Read more
16 May 2016 15:10

AGM, EGM Calendar - Week Ahead

Read more
8 Apr 2016 16:17

4D Pharma gobbles up Biomar production assets

(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.